Pro-Cure has actively recruited a strong and experienced executive management team, able to draw upon long track records of success in the biotechnology and pharmaceutical fields. Management is supported by a Board highly experienced in the development of businesses in biotechnology. Brief biographical details for senior members of Management include:

Mick McLean, CEO

• 20+ years in the biotechnology industry with leadership roles in the US, UK and EU
• Former President of Avecia Biotechnology (Boston, MA) and CEO of Oligovax (Paris); currently Chairman for Link Technologies Limited (Glasgow)
• Track record of leading organisations through change and rapid growth, negotiating deals and raising money

Norman Maitland, CSO

• Professor of Molecular Biology (University of York) and Director of the YCR Cancer Research Unit
• Past Chairman of the European Society for Basic Urological Research and the British Prostate Group, member of the MRC College of Experts
• Coordinator for, or participant in, EU collaborative projects in prostate cancer totalling >€20m

John Knights, CFO

• Highly experienced Finance Director and business professional in the telecommunications sector, with responsibility for collection of >£15bn in revenue
• Former FD of BT’s Business Division (including responsibility for O2 and Yell), and CEO for Argensys Limited
• Track record of developing and implementing effective business processes

David Gee, Business Development Director

• More than 20 years experience in business development and strategic planning for international healthcare companies
• Former COO of Altana Technology Products, managing $100M investment fund
• Executive management roles with Argenta Discovery, Byk Gulden, Pharmexa and Purdue Pharma
• Proven abilities in deal making and fund raising in biotechnology and healthcare